Financial Conflicts of Interest in FDA Advisory Committees

Findings point to important heterogeneities in financial ties

MilbankMemorialFund logo image
Doctors on FDA panels with ties to drug companies are more likely to vote in favour of that company’s drug…

When the Food and Drug Administration creates an advisory committee to help it decide whether to approve drugs, it often asks academic physicians to serve on the committee as external experts…

A study by Genevieve Pham-Kanter published in The Milbank Quarterly concluded:
There appears to be a pro-sponsor voting bias among advisory committee members who have exclusive financial relationships with the sponsoring firm but not among members who have non-exclusive financial relation-ships (ie, those with ties to both the sponsor and its competitors). These findings point to important heterogeneities in financial ties and suggest that policy-makers will need to be nuanced in their management of financial relationships of FDA advisory committee members“.

Sources and More Information:

Author: DES Daughter

Activist, blogger and social media addict committed to shedding light on a global health scandal and dedicated to raise DES awareness.

Have your say! Share your views

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.